Yeramaneni, 7,158 patient famotidine prophylaxis study: 51% lower mortality [p=0.22] https://c19p.org/yeramaneni
copied to clipboard
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011
Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use and lower risk with pre-existing use, without statistical significance in both cases.
|
risk of death, 51.0% lower, OR 0.49, p = 0.22, treatment 351, control 6,807, adjusted per study, home use, multivariable, RR approximated with OR.
|
|
risk of death, 59.0% higher, OR 1.59, p = 0.09, treatment 410, control 746, adjusted per study, hospital use, multivariable, RR approximated with OR, late treatment result.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Yeramaneni et al., 2/28/2021, retrospective, USA, North America, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.